Liver disease is frighteningly common worldwide. Metabolic dysfunction-associated steatotic liver disease, or MASLD, is an umbrella term describing conditions related to a buildup of fat in the liver.

Landmark trials have shown that GLP-1 receptor agonists, originally developed for diabetes and weight loss, also provide ...

Fact checked by Nick BlackmerI was first told that I was at higher risk for fatty liver disease in 2005. I had never heard the term before. My primary care provider didn't seem too concerned about ...

Metabolic dysfunction-associated steatohepatitis (MASH) represents a serious form of fatty liver disease that can lead to permanent damage while producing few noticeable symptoms.

The Food and Drug Administration is expected to approve the first medicine developed specifically to treat the serious liver disease known as MASH as soon as this week. The pill, called resmetirom ...

UAB researchers have reversed metabolic dysfunction-associated steatohepatitis (MASH) in mouse models. MASH is a severe liver disease associated with obesity and type 2 diabetes that affects more ...

Efimosfermin showed promise in reducing liver fat and maintaining safety across multiple doses in adults with phenotypic MASH.

In his 40s, Álvarez was diagnosed with fatty liver disease. Genetics can play a role, and he later learned that his mother had the same condition. "Navigating this journey has deepened my ...

Akero Therapeutics said Monday that extending treatment with its experimental drug for the liver disease known as MASH from six months to two years resulted in better outcomes for patients ...

This new therapeutic for advanced-stage liver disease is significant because, until now, ... Of that population, 20% have the more advanced disease form, MASH.

Madrigal’s stock surges as FDA approves first drug for liver disease MASH ‘Silent’ disease affects an estimated 5% of U.S. adults Last Updated: March 15, 2024 at 8:31 a.m. ET First Published ...